Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells

Abstract

Key Points Echinomycin can selectively kill the leukemia-initiating cell in relapsed AML without normal stem cell toxicity. In vivo delivery of echinomycin can induce long-term complete remission in a murine model of relapsed AML.